NEWS
2023.7.7
Decision to Relocate to the International Hub for HealthcareInnovation in Nakanoshima, Osaka
2022.4.4
2019.8.29
2019.3.5
2018.2.26
Website was launched.
GREETINGS
Research and Development (R&D)/Practical Use of Regenerative Medicines
With the aging of society, the number of patients with eye diseases that result in blindness has been increasing every year. However, transplantation therapy is facing great difficulties—that is the shortage of donated eyes and rejection, and thus, does not fully meet the expectation of patients. To overcome the difficulties, RAYMEI Inc. was established in 2016 to put regenerative medicine to practical use with a core technology of the SEAM method (R. Hayashi et al. Nature 2016) that recreates two-dimensionally induced eye-related cells, including the cornea and retina, developed by the Ophthalmology Class, Department of Neural and Sensory Organ Surgery, Graduate School of Medicine, Faculty of Medicine, Osaka University, led by Professor Koji Nishida.
The Osaka University laboratory has conducted First-in-Human clinical research since 2018 for allogeneic HLA homo-iPS cell-derived cultured corneal epithelial cell sheets in severe limbal stem cell deficiency (Stevens-Johnson Syndrome, ocular pemphigoid, heat/chemical injury, aniridia, etc.). The laboratory also plans to conduct clinical research on anterior chamber injection of allogeneic human iPS cell-derived corneal endothelial cells in severe bullous keratopathy. RAYMEI Inc. are simultaneously preparing for clinical studies so that we can deliver these therapies/regenerative medicines to patients as fast as possible, aiming at the development and clinical application of high-quality allogeneic iPS cell-derived corneal epithelial cell sheets and corneal endothelial cells. In the future, we will deploy our technology not only to the cornea but also to regenerative medicine in the ophthalmology area, including other tissues.
From R&D to clinical application, RAYMEI Inc. are striving to realize the Quality of Vision and Quality of Life of patients with eye diseases.
President
Masakazu Kobayashi
ABOUT US
Company Overview
Name
RAYMEI Inc.
Date of establishment
May 20, 2016
Headquarters
30 F, Osaka Ekimae Building No. 3, Umeda 1-1-3, Kita-ku, Osaka-shi, Osaka, 530-0001
Office
5 F, Bldg. D, Office of Industry-University Co-creation, Osaka University Yamadaoka 2-1, Suita-shi, Osaka 565-0871
Business Overview
Regenerative Medicine
Board Member
President :
Board Directors :
Auditor :
Scientific technical advisor :
Masakazu Kobayashi
Yasushi Hiramine, Koichi Baba
Shusei Kamata
Kohji Nishida
BUSINESS
Commercialize the research deliverables of regenerative medicine using iPS cells (SEAM method) by the Department of Ophthalmology, Faculty of Medicine, Osaka University, and put new therapies on eye diseases and related products into practical use.
The Ophthalmology Class, Faculty of Medicine, Osaka University has developed a two-dimensional tissue consisting of four concentric zonal structures, which recreates all eye-like structures by promoting the self-organization of differentiated iPS cells (self-formed ectodermal autonomous multi-zone: SEAM). To date, there have been reports on technologies that only induce the posterior part of the eye (retina and retinal pigment epithelium, etc.); however, our technology can simultaneously induce the anterior (cornea and crystalline lens, etc.) and posterior(retina and retinal pigment epithelium, etc.) parts of the eye.
On SEAM, the major cell groups that make up the developing eye (corneal epithelium, retina, and lens epithelium) appear in specific areas.
RAYMEI strives to first isolate corneal epithelial progenitor cells from the third band structures and corneal endothelial progenitor cells from the second band structure of SEAM, prepare functional corneal epithelial/endothelial cells, eventually producing high-quality corneal epithelial cell sheets and corneal endothelial cells and putting them to practical use.
We will further deploy the technology to other sites in the future.
CONTACT US
Please note that it may take some time to respond to your inquiry before/after weekends/holidays and depending on the contents of the inquiry.
